We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

83 hedge funds and large institutions have $223M invested in Lumos Pharma, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more call options, than puts

Call options by funds: $53.3M | Put options by funds: $12.1M

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

17% more funds holding

Funds holding: 7183 (+12)

8% more capital invested

Capital invested by funds: $206M → $223M (+$16.2M)

0% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 23

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
83
Holders Change
+12
Holders Change %
+16.9%
% of All Funds
2.41%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
20
Increased
23
Reduced
23
Closed
6
Calls
$53.3M
Puts
$12.1M
Net Calls
+$41.2M
Net Calls Change
+$10.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$29.5M -$12.7M -71,276 -32%
First Eagle Investment Management
2
First Eagle Investment Management
New York
$19.9M +$2.51M +14,089 +16%
PC
3
PointState Capital
New York
$18.2M -$3.46M -19,444 -17%
Franklin Resources
4
Franklin Resources
California
$17M +$15.3M +85,789 New
BFA
5
BlackRock Fund Advisors
California
$16.6M -$18.1K -102 -0.1%
Millennium Management
6
Millennium Management
New York
$12.1M +$3.17M +17,813 +41%
TAM
7
Tiverton Asset Management
Delaware
$11M
Vanguard Group
8
Vanguard Group
Pennsylvania
$10.2M +$386K +2,169 +4%
WSA
9
Wall Street Associates
California
$7.94M +$219K +1,233 +3%
Invesco
10
Invesco
Georgia
$6.35M +$88.6K +498 +2%
State Street
11
State Street
Massachusetts
$6.07M +$522K +2,935 +11%
Northern Trust
12
Northern Trust
Illinois
$5.33M +$107K +600 +2%
Barclays
13
Barclays
United Kingdom
$5.24M -$237K -1,333 -5%
UBS AM
14
UBS AM
Illinois
$5.03M +$4.52M +25,394 New
SBH
15
Segall Bryant & Hamill
Illinois
$4.45M
BIT
16
BlackRock Institutional Trust
California
$4.44M -$216K -1,215 -5%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$4.19M +$2.41M +13,562 +179%
EAM
18
Eventide Asset Management
Massachusetts
$3.46M +$3.11M +17,478 New
ERSOT
19
Employees Retirement System of Texas
Texas
$2.18M +$1.28M +7,222 +191%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$1.86M +$115K +647 +7%
Axa
21
Axa
France
$1.82M +$1.63M +9,185 New
Group One Trading
22
Group One Trading
Illinois
$1.8M +$1.61M +9,077 New
KCM
23
Knoll Capital Management
Florida
$1.7M
Geode Capital Management
24
Geode Capital Management
Massachusetts
$1.65M +$45.7K +257 +3%
Principal Financial Group
25
Principal Financial Group
Iowa
$1.63M +$23.7K +133 +2%

LUMO Hedge Fund Activity: Q4 2013 in Review

83 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2013, worth a combined $223M — up 7.9% from $206M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new LUMO positions and 6 closed out — a net gain of 14 holders — while 23 added to existing stakes and 23 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $15.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $36.4M sold.

  • 83 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2013, up from 71 in Q3 2013.
  • Funds reported $223M of Lumos Pharma, Inc. Common Stock stock for Q4 2013, up 7.9% quarter-over-quarter.
  • 20 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2013 and 6 closed out, a net change of +14 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2013 was Franklin Resources, an estimated $15.3M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2013 was RA Capital Management, an estimated $36.4M sold.

Based on aggregated 13F filings for Q4 2013.